A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

NCT05921162 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa
Retinal Disease
Retinal Degeneration

Interventions

BIOLOGICAL: Gene Therapy product:vMCO-I

Sponsor

Nanoscope Therapeutics Inc.